For most of the last three decades, a Hepatitis C diagnosis meant a lifetime of managing the virus, interferon injections with brutal side effects, and painful conversations about whether pregnancy was safe. Today, that story has completely changed. A short 8 to 12-week course of direct-acting antivirals (DAAs) now cures over 96% of Hepatitis C patients in India. The virus goes away and stays away.
For couples planning fertility treatment, this is a genuine paradigm shift. Curing Hepatitis C before starting IVF removes vertical transmission risk to the baby, improves ovarian response during stimulation, reduces miscarriage rates, and simplifies the entire treatment pathway. It also removes the emotional weight of wondering whether you will pass a chronic infection to your child.
At Delhi IVF and Fertility Research Centre, under the direction of Dr. Anoop Gupta, Hepatitis C-positive patients are counselled honestly about the "cure first, IVF next" pathway, and where DAA treatment cannot precede fertility care, safe alternative protocols are available. This blog explains exactly how the modern approach works, what it costs in India, and how it changes your fertility journey.
What is Direct-Acting Antiviral (DAA) Treatment for Hepatitis C?
Direct-acting antivirals (DAAs) are oral tablets that target Hepatitis C virus proteins directly, stopping the virus from replicating in the liver. Unlike the older interferon-based treatments, DAAs are well tolerated, taken as a single daily pill, and completed in just 8 to 12 weeks.
Common DAA combinations available in India include:
- Sofosbuvir plus velpatasvir (pan-genotypic, 12 weeks)
- Sofosbuvir plus ledipasvir (genotype 1, 4, 5 and 6, typically 12 weeks)
- Sofosbuvir plus daclatasvir (widely used in India, 12 weeks)
- Glecaprevir plus pibrentasvir (pan-genotypic, as short as 8 weeks)
The cure rate is measured by SVR12 (Sustained Virologic Response at 12 weeks), meaning HCV RNA is undetectable in the blood 12 weeks after finishing treatment. SVR is considered a permanent cure, and reinfection only occurs through new exposure.
India is one of the most affordable countries in the world for DAA therapy because of generic drug availability under Indian pharmaceutical patent law.
Why Curing Hepatitis C Before IVF is a Game-Changer for Couples
Completing DAA therapy before fertility treatment offers four powerful advantages:
- Eliminates vertical transmission risk to the baby: Without treatment, mother-to-child transmission of HCV is around 4 to 6%. Once the mother is cured with confirmed SVR, this risk becomes zero. No vaccine exists for Hepatitis C, so curing the virus is the strongest available protection.
- Improves ovarian response during IVF stimulation: Untreated HCV-positive women have been shown to require higher gonadotropin doses and experience higher rates of absent ovarian response compared to controls.
- Reduces miscarriage risk: The Italian PITER cohort found that HCV-positive women had significantly higher miscarriage rates, and that achieving SVR after DAA therapy meaningfully reduced this risk.
- Simplifies the entire treatment protocol: Once cured, no sperm washing, no special obstetric monitoring for HCV, no newborn testing schedule, and no coordination with a hepatologist during pregnancy is required.
Curing first is not always possible, but where it is possible, it delivers the safest and most straightforward pathway to a healthy baby.
How Does Hepatitis C Affect Fertility?
Chronic HCV infection can affect both partners in ways that are not always obvious.
Effect on Female Fertility
Research on HCV-positive women, including large cohort studies, has identified:
- Higher rates of impaired ovarian response during IVF stimulation
- Premature ovarian senescence with lower anti-Mullerian hormone (AMH) levels
- Higher miscarriage rates compared to HCV-negative women
- Lower clinical pregnancy rates per cycle in some studies
- Improved outcomes once SVR is achieved through DAA therapy
Effect on Male Fertility
The evidence for male HCV-positive patients is more mixed:
- Some studies show altered sperm parameters and DNA fragmentation
- Anti-sperm antibodies have been documented at higher rates in HCV-positive men
- Other studies find no significant difference in sperm quality
- HCV RNA is detectable in seminal plasma and can be removed by sperm washing
For couples where either partner is HCV positive, a full male infertility treatment workup and female fertility assessment before starting DAA therapy help set realistic timelines for the entire journey.
What is the Recommended Timeline: DAA Treatment First, Then IVF?
The evidence-based sequence looks like this:
| Step | Timeline | What happens |
| Hepatology consultation | Week 0 | HCV RNA quantification, genotype, LFT, FibroScan |
| DAA therapy | Weeks 1 to 12 | Daily oral tablet, minimal side effects |
| End-of-treatment HCV RNA | Week 12 | Confirms undetectable virus at end of therapy |
| SVR12 confirmation | Week 24 | Sustained virologic response = permanent cure |
| Fertility workup starts | Week 24 to 28 | Hormonal profile, ovarian reserve, semen analysis |
| IVF cycle begins | Week 28 onwards | Standard IVF or ICSI with no HCV-specific modifications |
For couples where age or ovarian reserve is a pressing factor, ovarian reserve testing and fertility preservation options can be discussed at Delhi IVF alongside DAA treatment, so no time is lost.
What if I Cannot Wait to Cure Hepatitis C Before IVF?
Some couples cannot delay fertility treatment for six months. Advanced maternal age, low ovarian reserve, and other time-sensitive fertility factors sometimes require an alternative approach. Where a DAA cure cannot precede IVF, safe protocols include:
- Sperm washing plus ICSI for HCV-positive men, using density gradient centrifugation, swim-up, and HCV RNA testing of the processed sample. This is the same evidence-based procedure detailed under sperm washing for HIV, Hepatitis B and Hepatitis C positive fathers.
- Careful obstetric monitoring for HCV-positive women, with viral load checks during pregnancy, standard delivery planning, and newborn HCV testing at 18 months (or earlier by RNA testing at 2 to 6 months)
- DAA therapy during pregnancy is now emerging as an option internationally, with Indian and US phase 1 studies showing 100% cure rates and no congenital abnormalities. It is not yet routine practice in India and should be discussed with a hepatologist.
Where possible, completing DAA therapy first remains the recommended approach.
What is the Cost of DAA Treatment and IVF in India?
India is one of the most affordable destinations globally for Hepatitis C cure because of generic DAA availability.
| Component | Estimated cost (INR) |
| Hepatology consultation and workup | 3,000 to 8,000 |
| HCV RNA quantitative test | 2,500 to 5,000 |
| HCV genotype test | 3,000 to 6,000 |
| FibroScan (liver stiffness) | 2,500 to 5,000 |
| DAA therapy (12-week course, generic) | 25,000 to 80,000 |
| SVR12 confirmation test | 2,500 to 5,000 |
| Complete IVF cycle with ICSI | 1,50,000 to 2,50,000 |
| Optional genetic screening (PGT) | 60,000 to 1,20,000 |
| Sperm washing (if IVF cannot wait for cure) | 25,000 to 60,000 |
At Delhi IVF, all costs are itemised transparently at your first consultation, and financial planning support is available for couples undergoing DAA therapy and IVF across cycles.
Are DAAs Safe? What About Side Effects?
Modern DAAs are among the best-tolerated antiviral treatments in medicine. Most patients complete the 8 to 12-week course with minimal disruption to daily life.
The most commonly reported side effects are:
- Mild fatigue
- Headache
- Mild nausea in the first days of treatment
- Occasional trouble sleeping
Severe side effects are rare. Unlike older interferon-based regimens, DAAs do not cause depression, flu-like symptoms, or bone marrow suppression. Your hepatologist monitors liver function periodically during treatment. Once DAA therapy is complete, no long-term maintenance medication is required.
Why Choose Delhi IVF for Post-Cure Fertility Treatment?
- 34+ years of fertility expertise under Dr. Anoop Gupta, with Delhi's first ICSI baby delivered in 1996
- 25,000+ successful deliveries across a wide range of complex cases, including couples with a history of viral hepatitis
- Coordinated multidisciplinary care by Dr. Aastha Gupta, integrating your fertility treatment with your hepatologist during and after DAA therapy
- Fertility preservation options including egg and sperm freezing so you can safeguard reproductive potential while completing DAA cure
- Complete confidentiality across all patient records, consultations and cycle documentation
- Full range of assisted reproduction services including IUI, IVF, ICSI, male infertility treatment, and surgical sperm retrieval
- Compassionate, non-judgemental counselling at every stage of your journey from cure to conception
Book Your Confidential Consultation
If you or your partner has been diagnosed with Hepatitis C and you want to start or grow your family, you no longer have to choose between managing the virus and having a baby. Modern DAA therapy plus expert fertility care at Delhi IVF and Fertility Research Centre offers a clear, cure-first pathway to healthy parenthood.
